Cat. No：GM-88264AB
Product：Anti-PD1-IL2v Fusion hIgG1 Antibody(2149)
Cat. No：GM-88264AB
Product：Anti-PD1-IL2v Fusion hIgG1 Antibody(2149)
GM-88264AB-10 10 μg
GM-88264AB-100 100 μg
GM-88264AB-1000 1mg
Species Reactivity | Human; |
Clone | 2149 |
Source/Isotype | hIgG1 (KDEL,L234A/L235A /N297A), Kappa |
Application | Activation assay |
Specificity | Detects PD1&IL2RA |
Gene | PD1&IL2RA |
Other Names | PD1: NACP, PARK1, PARK4, SNCA |
IL2RA, IL2Rα | |
Gene ID | PD1 (6622) |
Background | The PD-1/PD-L1 pathway inhibits T cell activity to maintain immune tolerance and block tumor immune escape; relatively, IL-2/IL-2R is a key growth factor in the initial activation phase, promoting T cell proliferation with functional maintenance. In tumor microenvironment, inhibition of PD-1/PD-L1 may reduce the production and response of IL-2, impair amplification and memory formation; The signal intensity of IL-2R affects the reactivation sensitivity of inhibited T cells and the maintenance of anti-tumor effect. IL-2R promotes proliferation versus survival via JAK-STAT (especially Stat5) , whereas PD-1 inhibits TCR/JAK-STAT via Shp-2, possibly attenuating the balance of amplification of IL-2R signaling versus functional differentiation. This coupling suggests that simultaneous enhancement of IL-2/IL-2R signaling in combination therapy synergistically elevates the reactivation of suppressed T cells with the formation of durable antitumor memory. |
Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
Formulation | 20 mM Histidine, 100 mM NaCl, pH 6.0 |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Cat. No：GM-88264AB
Product：Anti-PD1-IL2v Fusion hIgG1 Antibody(2149)
GM-88264AB-10 10 μg
GM-88264AB-100 100 μg
GM-88264AB-1000 1mg
Species Reactivity | Human; |
Clone | 2149 |
Source/Isotype | hIgG1 (KDEL,L234A/L235A /N297A), Kappa |
Application | Activation assay |
Specificity | Detects PD1&IL2RA |
Gene | PD1&IL2RA |
Other Names | PD1: NACP, PARK1, PARK4, SNCA |
IL2RA, IL2Rα | |
Gene ID | PD1 (6622) |
Background | The PD-1/PD-L1 pathway inhibits T cell activity to maintain immune tolerance and block tumor immune escape; relatively, IL-2/IL-2R is a key growth factor in the initial activation phase, promoting T cell proliferation with functional maintenance. In tumor microenvironment, inhibition of PD-1/PD-L1 may reduce the production and response of IL-2, impair amplification and memory formation; The signal intensity of IL-2R affects the reactivation sensitivity of inhibited T cells and the maintenance of anti-tumor effect. IL-2R promotes proliferation versus survival via JAK-STAT (especially Stat5) , whereas PD-1 inhibits TCR/JAK-STAT via Shp-2, possibly attenuating the balance of amplification of IL-2R signaling versus functional differentiation. This coupling suggests that simultaneous enhancement of IL-2/IL-2R signaling in combination therapy synergistically elevates the reactivation of suppressed T cells with the formation of durable antitumor memory. |
Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
Formulation | 20 mM Histidine, 100 mM NaCl, pH 6.0 |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
